RGCC
20 Years of Technological Innovation
Decoding Cancer with Scientific Logic, Rebuilding the Future of Integrative Medicine through Systems Medicine
2004 — Founding and Beginnings
RGCC Precision Cancer Medicine Center was founded in Greece by genetics pioneer Dr. Ioannis Papasotiriou.
Official launch of the world’s first integrative Onconomics Plus™ tumor sensitivity test.
2011 — Breakthrough in Cancer Stem Cells
First to identify the critical role of cancer stem cells (CSCs) in tumor evolution and precision therapy.
Initiated RGCC’s research on precision assessment and intervention models targeting the root mechanisms of cancer.
2014 — Precision Biomarkers and Next-Generation Testing
Identified TMX2 as a novel potential biomarker for breast cancer.
Launched ChemoSNip®, a predictive test for chemotherapy sensitivity.
Released Metastat®, a monitoring test for metastasis risk.
2017 — International Recognition and Global Expansion
RGCC-supported team won the Best Therapeutics Project Award at the International iGEM Synthetic Biology Competition.
Established RGCC’s first advanced laboratory in Asia (India).
2019 — Multiple Core Precision Testing Technologies Released
Launched CAMBISeq® for tumor genetic variation analysis.
Released aCGH®, a chromosomal microarray analysis test.
Introduced Immune-Frame®, a comprehensive immune system function test.
2020 — Expansion of International Clinical Education
Hosted a large-scale Integrative Oncology Symposium in Melbourne, Australia.
2021 — A Year of Next-Generation Innovations
Developed high-potency Genistein capsule formulations.
Created a novel SARS-CoV-2 virus screening technology.
Introduced the groundbreaking Clavic-Q-re® T-cell therapy for breast cancer and multi-cancer integrative treatments.
Established a dedicated RGCC Physician Service Center in North America.
Supported PNOIA Team in winning another award at the iGEM International Synthetic Biology Competition.
2022 — Record-Breaking Achievements in Synthetic Biology
Supported DIAS Team in winning another international iGEM award.
Further solidified RGCC’s leadership in global cancer research and innovation.
2023 — Southeast Asia Expansion and Global Integration Peak
Officially launched Onconomics Extracts+™, a plant-derived compound sensitivity test.
Established new branches in Singapore, Malaysia, and China, integrating precision testing with natural therapies.
Successfully hosted the RGCC Global Medical Leaders Summit in Switzerland.
2024 — Reaching the Pinnacle of International Biotechnology
Ranked among Switzerland’s Top 10 Biotechnology Companies of 2023.
Released the groundbreaking Onco-D-clare™ early cancer screening test.
Once again led the global era of precision cancer screening and innovation.
